DUBAI, UAE, Oct 17, 2024 - (ACN Newswire via SeaPRwire.com) - The Global STEM Education Confex is back for its 11th edition, hosted by IBEForuM, happening on 6-7 November 2024 promises to be an unparalleled platform for knowledge exchange, collaboration, and innovation among educators, researchers, policymakers, and industry leaders. Set against the backdrop of the stunning Millennium Plaza Downtown Hotel in Dubai, this premier event is designed to connect thought leaders and drive the future of STEM education.This year’s Confex will gather top-notch speakers from around the globe, including 29 distinguished speakers and representatives from education ministries. With over 500+ delegates expected to attend from various countries, the conference is set to be a vibrant hub of ideas and solutions. The event is supported by 26 media partners and 22 sponsors, from across the globe with more to be announcedEvent Highlights:Engage with Policymakers and Industry Leaders: Collaborate to align STEM education with industry needs, ensuring a workforce equipped for future challenges.Hands-on Workshops and Interactive Labs: Participate in immersive sessions that provide practical insights and applicable skills in STEM education.Global Collaboration Opportunities: Network with educators, researchers, and innovators from around the world to discover potential partnerships.Explore Cutting-edge Advancements: Stay informed about the latest technologies and educational tools transforming STEM learning.Join us for this prestigious event, where STEM education and innovation meet to create lasting global impact. We look forward to welcoming you to Dubai!Event Details:Date: 6-7 NovemberVenue: Millennium Plaza Downtown Hotel, Dubai, UAEAbout IBEForuMIBEForuM is an International Organization with the goal of empowering global leaders to carve a better future. We are here to solve our shared global challenges through the power of collaboration. We help your business to build a sustainable future by synergizing ideas and infusing innovative solutions. Our insights and quality services help build trust and confidence giving birth to a ground-breaking alliance between academic research and practitioners thus helping them excel in this era of the digital revolution.Our extensive cross-industry connections bring together high calibre, industry leaders to provide the latest policy updates, strategic insight, and practical guidance. We deliver a broad range of industry-specific services that help create valuable relationships between our clients, their customers, employees, and regulatory authorities. We drive transformation by leveraging our cross-functional expertise across various domains. For more information, visit www.ibeforum.com.Speaking and Sponsorship Opportunities:For those interested in contributing to this significant event:Speaking Opportunities:Contact Arif Ulla+91 9845-113-293Email - arif.ulla@ibeforum.com Sponsorship Opportunities: Reach out to Imroze Shaik +91 9901-955-118Email - imroze.shaik@ibeforum.com Copyright 2024 ACN Newswire via SeaPRwire.com.
SHANGHAI, Oct 21, 2024 - (ACN Newswire via SeaPRwire.com) - Everest Medicines (HKEX 1952.HK, “Everest”, or the “Company”), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announces that the Taiwan Food and Drug Administration (TFDA) has approved NEFECON® indicated “to reduce the loss of kidney function in adult patients with primary immunoglobulin A nephropathy (IgAN) who are at risk for disease progression1”. There are no restrictions on initial proteinuria levels in the approved indication. This marks the expansion of NEFECON®, the world's first and only IgAN etiological treatment drug fully approved by the U.S. Food and Drug Administration (FDA), to more IgAN patients."The approval of NEFECON® in Taiwan, China is another milestone for NEFECON®, following approvals in Singapore, Hong Kong, and the commercial launch in Mainland China this year.” said Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines. “IgAN is prevalent in the Asian population, which has 56% higher risk of progression to end-stage renal disease and faster disease progression, indicating a significant unmet clinical demand. In the future, we will continue to expand the access of NEFECON® across Asia to bring this first-in-disease therapy to more patients."The global Phase 3 NefIgArd clinical trial showed that compared to placebo, NEFECON® not only brought about a sustained reduction in proteinuria and reduced the frequency of microscopic hematuria but also demonstrated clinically relevant and statistically significant treatment benefits in estimated glomerular filtration rate (eGFR) (p<0.0001), reducing the decline in kidney function by 50% and potentially delaying the progression to dialysis or kidney transplantation by 12.8 years.Taiwan, China is the fifth region in Everest Medicines' authorized area to approve NEFECON® after Macau, Mainland China, Singapore, and Hong Kong. As the core product of Everest Medicines in the field of nephrology, NEFECON® was also submitted for new drug application in South Korea at the end of 2023 and successfully accepted. In May of this year, the first prescription was issued in Mainland China. In July this year, the China’s National Medical Products Administration has accepted the submission of a supplemental new drug application seeking full approval of NEFECON® based on the complete clinical data from the global Phase 3 NeflgArd study, and NEFECON® is expected to become the first and only fully approved IgAN etiological treatment drug in China.In addition, NEFECON® is expected to be included in the first Chinese IgAN guidelines, recommended as the 1L treatment for IgAN patients at risk of disease progression.About NEFECON®NEFECON® is a patented oral, delayed release formulation of budesonide, a corticosteroid with potent glucocorticoid activity and weak mineralocorticoid activity that undergoes substantial first pass metabolism. The formulation is designed as a delayed release capsule that is enteric coated so that it remains intact until it releases budesonide to the distal ileum. Each capsule contains coated beads of budesonide that target mucosal B-cells present in the ileum where the disease originates, as per the predominant pathogenesis models.In June 2019, Everest Medicines entered into an exclusive, royalty-bearing license agreement with Calliditas Therapeutics, which gives Everest Medicines exclusive rights to develop and commercialize NEFECON® in Mainland China, Hong Kong, Macau, Taiwan, China and Singapore. The agreement was extended in March 2022 to include South Korea as part of Everest Medicine's territories.About global Phase 3 NefIgArd clinical trialThe global Phase 3 NefIgArd clinical trial was a randomized, double-blind, multicenter study that evaluated the efficacy and safety of NEFECON® (16 mg/d, once daily) compared to placebo in adult patients with primary IgA nephropathy treated with optimized RAS inhibitors. The study lasted for 2 years, including a 9-month NEFECON® or placebo treatment period, followed by a 15-month drug withdrawal follow-up period.The complete 2-year data of the NefIgArd study (n=364) further analyzed the potential differences in the response to NEFECON® treatment between Asians (n=83) and Caucasians (n=275). The results showed that compared to placebo, both Asians and Caucasians treated with NEFECON® for 9 months can significantly delay the decline of eGFR, protect kidney function, and bring about a sustained reduction in proteinuria and reduce the risk of microscopic hematuria.About Everest MedicinesEverest Medicines is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing transformative pharmaceutical products and vaccines that address critical unmet medical needs for patients in Asian markets. The management team of Everest Medicines has deep expertise and an extensive track record from both leading global pharmaceutical companies and local Chinese pharmaceutical companies in high-quality discovery, clinical development, regulatory affairs, CMC, business development and operations. Everest Medicines has built a portfolio of potentially global first-in-class or best-in-class molecules in the company’s core therapeutic areas of renal diseases, infectious diseases and autoimmune disorders. For more information, please visit its website at www.everestmedicines.com.Forward-Looking Statements:This news release may make statements that constitute forward-looking statements, including descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the business operations and financial condition of the Company, which can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “confident” and similar statements. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, or other factors, some of which are beyond the control of the Company and are unforeseeable. Therefore, the actual results may differ from those in the forward-looking statements as a result of various factors and assumptions, such as future changes and developments in our business, competitive environment, political, economic, legal and social conditions. The Company or any of its affiliates, directors, officers, advisors or representatives has no obligation and does not undertake to revise forward-looking statements to reflect new information, future events or circumstances after the date of this news release, except as required by law.References1.TFDA approved indication. Copyright 2024 ACN Newswire via SeaPRwire.com.
HONG KONG, Oct 21, 2024 - (ACN Newswire via SeaPRwire.com) - With the increasing global emphasis on sustainability, the Hong Kong government has introduced the 'Hong Kong's Climate Action Plan 2050'. To enhance the transparency of environmental governance and climate-related disclosure for listed companies, HKEX has also revised the "ESG Code" to be effective from 1 January 2025. Within this evolving framework, Corporate Social Responsibility (CSR) and Environmental, Social, and Governance (ESG) factors have emerged as pivotal foundations for business development. This is particularly evident in Hong Kong's construction industry, where numerous companies proactively champion these initiatives to demonstrate a steadfast commitment to a sustainable future.As a good model among Hong Kong listed companies in construction industry, Ching Lee Holding Limited (3728. HK) is advancing its ESG agenda through a variety of initiatives. Notably, Ching Lee participated in the "ESG Pledge Scheme" this year organised and recognised by The Chinese Manufacturers' Association of Hong Kong. This initiative reinforces Ching Lee's leadership role in promoting ESG principles and highlights its proactive stance on sustainability.Employees' welfare and occupational health and safety are always the most important items on the ESG agenda. Ching Lee ensures preparedness on construction sites and conducts emergency drills regularly. This dedication reflects its responsible commitment and a profound respect for employee safety. Moreover, the company places a high value on enhancing employee skills. According to Ching Lee's annual report, the total training hours for employees reached an impressive 98.5 hours, with a training participation rate of approximately 60%. Employees are also integral participants in the ESG framework. Several companies have established training systems that align employee development closely with corporate sustainability objectives, thereby achieving a mutually beneficial outcome.In addition to prioritising occupational safety and skills training, Hong Kong companies support public welfare projects in education, healthcare, and culture, while encouraging employees to engage in community service. According to the annual report from Ching Lee Holdings, the company donated over HKD 1.5 million to various charitable organisations in the 2023-2024 financial year, with more than 60 employees actively participating in community service. Furthermore, Ching Lee commits to promoting green building technologies and mandates that all employees adhere rigorously to environmental standards throughout construction. For instance, the company advocates for using recyclable building materials and strives to minimise waste generation during construction activities in addition to energy-saving and emission-reduction measures.By implementing a comprehensive range of initiatives, Hong Kong companies enable their workforce to become active participants in ESG efforts. Ching Lee Holdings adeptly links corporate development with employee growth, illustrating that corporate social responsibility is not merely essential but constitutes a fundamental pillar of sustainable development. Copyright 2024 ACN Newswire via SeaPRwire.com.
Luxembourg, Oct 16, 2024 - (ACN Newswire via SeaPRwire.com) - Moolec Science SA (NASDAQ:MLEC) ("the Company"), a leader in Molecular Farming technology, announced today that the U.S. Department of Agriculture's ("USDA") Animal and Plant Health Inspection Service ("APHIS") has completed its Regulatory Status Review ("RSR") for the Company's genetically engineered ("GE") peas which produce iron through bovine meat proteins. This is the third regulatory clearance from USDA-APHIS achieved by Moolec in an 18-month window, alongside its genetically engineered safflower and soybean for GLASO™ and Piggy Sooy™ products, respectively. Access the official USDA-APHIS publication here."With USDA approval for our GE pea, Moolec has now secured regulatory clearance for all of our key crops in the US: safflower, soybean, and pea," said Gastón Paladini, CEO and Co-Founder of Moolec. "We are proud to be the only Molecular Farming company with three US regulatory approvals and a major commercial contract. This milestone underscores our leadership in the landscape with tangible, science-backed results."Moolec's genetically engineered peas produce high yields of bovine myoglobin, a protein that boosts iron content, making it an ideal alternative for consumers seeking plant-based sources of iron. This product has the potential to revolutionize both the food ingredient market and the $65 billion pea industry by offering a nutritious, iron-rich alternative to traditional meat products.Amit Dhingra, Chief Science Officer for the Company, stated, "The USDA-APHIS Regulatory Status Review for pea marks a significant milestone for Moolec. As the first review for GE pea, it represents a historic development. It validates Moolec's strategic approach and exemplifies our commitment advancing sustainable food production through science and innovation. This approval is a critical step toward enhancing global food supply and meeting the growing demand for innovative, nutritious food solutions for the world."This approval not only showcases Moolec's innovation in Molecular Farming but also highlights the company's commitment to meeting the highest regulatory and safety standards. Moolec has also developed an Identity Preservation Program to ensure sustainable farming practices, promote stewardship for its crops and product quality for partners, clients and consumers alike.According to USDA-APHIS regulation found at 7 CFR part 340, developers may submit a request for a RSR when they believe a GE plant is not subject to the regulation. APHIS reviews the GE plant and considers whether it might pose an increased plant pest risk compared to its non-GE comparator. If APHIS does not identify a greater pest risk relative to the comparator, the GE plant is not subject to this regulation. Regulation 7 CFR part 340 governs the importation, interstate movement, and the environmental release of certain organisms that have been modified or produced by genetic engineering.The USDA-APHIS review process is a critical component of ensuring that genetically engineered crops can be grown safely, and this approval opens the floor for expanded field trials, seed scaling, and eventual commercialization. With increasing interest in science-based ingredients, this approval positions the company to lead a new wave of innovation in the food and agriculture sectors.About Moolec Science SAMoolec is a science-based ingredient company leader in the use of Molecular Farming technology for food and dietary supplementation markets. The Company's mission is to create unique food ingredients by engineering plants with animal protein genes. Its purpose is to redefine the way the world produces animal proteins for the good of the planet. Moolec's technological approach aims to have the cost structure of plant-based solutions with the nutrition and functionality of animal-based ones. Moolec's technology has been under development for more than a decade and is known for pioneering the production of a bovine protein in a crop for the food industry. The Company's product portfolio and pipeline leverage the agronomic efficiency of broadly used target crops like soybean, pea, and safflower to produce oils and proteins. Moolec also has an industrial and commercial R&D capability to complement the company's Molecular Farming technology. Moolec secures a growing international patent portfolio (25+, both granted and pending) for its Molecular Farming technology. The Company is run by a diverse team of PhDs and Food Insiders, and operates in the United States, Europe, and South America. For more information, visit moolecscience.com and ir.moolecscience.com.Forward-Looking StatementsThis publication contains "forward-looking statements." Forward-looking statements may be identified by the use of words such as "forecast," "intend," "seek," "target," "anticipate," "believe," "expect," "estimate," "plan," "outlook," and "project" and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements with respect to performance, prospects, revenues, and other aspects of the business of Moolec are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Although we believe that we have a reasonable basis for each forward-looking statement contained in this publication, we caution you that these statements are based on a combination of facts and factors, about which we cannot be certain. We cannot assure you that the forward-looking statements in this publication will prove accurate. These forward-looking statements are subject to a number of significant risks and uncertainties that could cause actual results to differ materially from expected results, including, among others, changes in applicable laws or regulations, the possibility that Moolec may be adversely affected by economic, business and/or other competitive factors, costs related to the scaling up of Moolec's business and other risks and uncertainties, including those included under the header "Risk Factors" in Moolec's Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission ("SEC"), as well as Moolec's other filings with the SEC. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, you should not put undue reliance on these statements.Contact InformationPress & Mediacomms@moolecscience.comInvestor Relationsir@moolecscience.comRelated FilesMoolec Has Received USDA Approval For The First Genetically Modified Pea In HistorySOURCE: Moolec Science Copyright 2024 ACN Newswire via SeaPRwire.com.
HONG KONG, Oct 18, 2024 - (ACN Newswire via SeaPRwire.com) - CITIC Telecom International CPC Limited (“CITIC Telecom CPC”), a wholly-owned subsidiary of CITIC Telecom International Holdings Limited (SEHK: 1883) is at the forefront of AI+ innovation era, enabling dual empowerment of technology and data, and fostering a new business model of intelligence and innovation across industries. CITIC Telecom CPC has further unleashed multiple AI+ projects powered by “AI+ Cloud, Network, Security” framework, the integration of AI technology with big data analytics and security capabilities, and vital customer experience, fueling innovative AI+ applications across industries to reshape the Intelligence Operation Journey of enterprises.CITIC Telecom CPC collaborates with partners to co-create AI+ EcosystemFrom “Technology Empowerment”(+AI) to “Data Empowerment” (AI+)AI has become a cornerstone in today’s business landscape. As a leading Global-Local Intelligent DICT Service Partner, CITIC Telecom CPC fully embraces the global digitalization era and proactively deploys the visionary “ICT-MiiND” framework. This framework seamlessly integrates an “innovative” technology stack, the power of algorithms and big data into the ICT service platform, spanning across “Cloud, Network, Security” and bolstering the element of “intelligence” through cutting-edge AI technology and AIOps modules. CITIC Telecom CPC believes in the transformative power of AI+, actively enhances the in-depth integration of AI across various industries, driving innovative projects from focusing on "Big Data Modelling" to "Small-Scale Scenario implementation". CITIC Telecom CPC has not only deployed extensive resources in AI technologies, but also deeply integrated generative AI applications across the full-chain technology modules, evolving from Technology Empowerment (+AI) to Data Empowerment (AI+), ushering in a new era driven by AI algorithms and big data. AI+ covers diverse AI technologies and applications, integrating big data platforms with small-scale scenario models. This approach covers data collection, storage, governance and mining through deep algorithms, machine learning, and intelligent analysis, to develop a range of intelligent applications and AI+ solutions. Tailored to meet enterprise needs, it provides a one-stop service from business transformation to strategic analysis, efficiently fulfilling enterprise requirements.“CITIC Telecom CPC strives to integrate large AI models with diverse AI+ applications in small-scale scenarios, empowering customers to advance intelligent capabilities, unlocking a realm of new possibilities,” said Mr. Brook Wong, CEO of CITIC Telecom CPCMr. Brook Wong, Chief Executive Officer of CITIC Telecom CPC, said, “Striding from +AI to AI+, CITIC Telecom CPC pioneers AI technologies with a steadfast commitment to ‘Innovation Never Stops', continuously optimizes “Cloud, Network, Intelligence, Security” "solutions, and accelerates the development of intelligence-enabled industries. We actively dedicate various resources and collaborate with partners to co-create a prosperous AI+ ecosystem, enrich technical infrastructure, lead our team and the industry towards a generative AI era driven by large language models, AI technologies, data and intelligent analysis. We strive to integrate large AI models with diverse AI+ applications in small-scale scenarios, empowering customers to advance intelligent capabilities, unlocking a realm of new possibilities.”Transformative AI+ Solutions Generate New Driving Force for Data & Security ApplicationsCITIC Telecom CPC stands at the forefront of AI technology. With decades of ICT experience and industry expertise, its data science and innovation teams are propelling AI innovations with cutting-edge algorithms and deep learning techniques, unlocking data value and accumulating a range of generative AI applications for enterprises. The team has developed a series of award-winning and groundbreaking AI+ solutions such as the newly-launched AI Databank and AI Pentest, driving operational efficiency and cost savings for enterprises.AI Databank – Powering Big Data with Fast, Accurate & Actionable Insights on a Single PlatformAI Databank integrates tremendous data from various business systems, collecting a wide array of internal and external information (such as CRM and ERP). Utilizing generative AI technology, enhanced by deep learning and big data training, it enables efficient data management and real-time report generation. Users can interact with the platform to quickly retrieve data and multiple real-time data charts through dialog-based data queries, empowering data-driven decision making. AI Databank also analyzes current and historical data to build forecast models, helping companies in future planning.AI Pentest – Redefining Vulnerability Assessment with Proactive, Secure and Intelligent AutomationCITIC Telecom CPC has successfully led the Security Operations Center (SOC) to enter into a new AI-driven era since the launch of "TrustCSI™ 3.0" cybersecurity solution at the end of last year. The newly-launched AI Pentest plays a key role in the security portfolio. It is a lightweight solution powered by unique AI-driven bypass techniques to expose WAF vulnerabilities, enabling automated routine task scheduling to simplify the assessment of internal network asset and empower enterprises to keep pace with the rapidly changing IT environment. AI Pentest functions as an AI robot cleaner which automatically operates 24x7, helping enterprises identify key vulnerabilities in the network and establish a robust defense against potential threats.CITIC Telecom CPC's AI+ solutions have been implemented in various industries to foster integration of diverse AI+ applicationsAI+ Reshapes Industries with New Scenarios & Business ValuesCITIC Telecom CPC's AI+ solutions have been implemented in various industries to foster integration of diverse AI+ applications, assisting customers in incorporating generative AI technology, deep learning and data applications, empowering digital transformation for enterprises including:- AI+TelecommunicationsCITIC Telecom CPC leverages AI+ innovation capabilities to create a "Network and Information Security Threats Identification Algorithm Model". Leveraging Natural Language Processing (NLP), algorithm models and innovative technical architecture, an "AI+ telecommunications industry" application platform is created. The platform uses large AI security industry models to learn and identify scams as well as the patterns and characteristics of fraudulent calls. A repetitive learning and training cycle, integrated deep learning capability, on a large amount of known scams and fraudulent calls data is conducted to automatically identify new suspicious calls in the network immediately, greatly improving the accuracy of analysis and interception, and generating values for the society.Use case: Developed by CITIC Telecom, “AI+ Digital and Intelligent Cross-border Mobile Network Security Service Platform” project has won multiple distinguished awards in the market. The project utilizes Voice/Signaling/SMS firewall interception to help major telecommunications service providers, mobile service operators and enterprise sector to enable real-time alerts and interception of illegal and fraudulent Voice/SMS messages. The cloud-based platform can be utilized in local and cross-border cross-network scenarios to identify SMS messages from international countries to mainland China and inter-country communications. The solution effectively helps citizens identify registered SMS senders to stop fraudsters from sending scam SMS messages masquerading as other companies or organizations.- AI+ ManufacturingAs the global manufacturing industry is booming rapidly, the integration with different new technologies is accelerating. Powered by AI, enterprises actively deploy multiple AI tools, diverse application scenarios and big data to build an innovative digital and intelligence ecosystem. Industry chain not only enhances production efficiency and quality, but also responds to changes efficiently through digital planning and intelligent analysis, and also devises more precise future operations plans. AI-driven data security solutions provide enterprises with instant responses to security threats,enhanced data and cyber security, secure and intelligent manufacturing environment, elevating intelligent production to a new level.Use case: CITIC Dicastal, the first lighthouse factory in the global aluminum wheel industry, paved the way for its transformation journey with pivotal support from CITIC Telecom CPC and its subsidiary China Entercom in establishing a secure, efficient and fast data highway. This initiative enabled seamless connectivity among its global factories and significantly enhanced its digital and intelligent operational management capabilities. Leveraging its industry expertise, insights and technical knowledge, CITIC Telecom CPC’s Innovation team empowered CITIC Dicastal to overcome networking and security challenges across various application scenarios, including AI-driven manufacturing, process optimization, R&D design, operational decision-making, green and low-carbon initiatives, facilitating to build a “Vertical Industry Big Model of Aluminum Automobile Parts”, enhancing production efficiency and intelligence. CITIC Telecom CPC’s “AI+ Cloud, Network, Security” not only empowers the intelligent enhancement of CITIC Dicastal's entire industry chain but also reinforces its "AI+ Security" capabilities, refines real-time response alerts and develops interconnection across global factories while effectively monitoring information security threats. These initiatives strengthen the cornerstone of information security, forging a new era for the “Lighthouse Factory”. - AI+ AutomobileDemand forecasting is the most important part of the digital and intelligent transformation of an enterprise's supply chain. CITIC Telecom CPC's "Intelligent Order Demand Forecasting Solution" utilizes AI technology to predict complex and fragmented materials, improving the forecasting accuracy of order demand for vehicle models, and dynamically adjusting materials and production capacity planning.Use case: Headquartered in Europe, a world-renowned automobile parts supplier operates in 29 countries and regions, and serves various well-known automobile brands around the world. CITIC Telecom CPC’s "Intelligent Order Forecast Solution" enables customers to increase forecast accuracy to over 80%, optimize supply chain management, and achieve cost reduction and efficiency improvement.- AI+ RetailThe retail industry is undergoing a large-scale implementation of AI applications. CITIC Telecom CPC's “Cloud, Network, Intelligence, Security” integrated platform help enterprises build a secure, efficient and flexible digital infrastructure, enhance network transmission, information security, cloud computing resources and AI platform capabilities through dynamic perception, predictions and intelligent alerts for networks and applications. Harnessing AI technology and data analysis, we facilitate enterprises in expediting their digital transformation. By enhancing traditional workflow designs with scenario templates like customer service management, R&D evaluation, and marketing reports, strategically utilize big data to reinvent business to seize market opportunities.Use case: A world-renowned cosmetics retail brand has been committed to scientific research and innovation for many years. CITIC Telecom CPC's “AI+ Cloud, Network, Security” integrated platform helps to build a secure, efficient and flexible digital infrastructure. The dynamic perception of networks and applications, predictions and intelligent alerts for networks and applications assist the cosmetics retail brand to realize the values of “In Shanghai, For China, and Connect the World" to meet the needs of consumers in mainland China and around the world.To know more information aboutFrom “Technology Empowerment” (+AI) to “Data Empowerment” (AI+),please visit https://www.citictel-cpc.com/en-hk/ict-miindAbout CITIC Telecom CPCWe are CITIC Telecom International CPC Limited (“CITIC Telecom CPC”), a wholly-owned subsidiary of CITIC Telecom International Holdings Limited (SEHK: 1883), serving multinational enterprises the world over by addressing their specific ICT requirements with highly scalable tailored solutions built upon our flagship technology suites, comprising TrueCONNECT™ private network solutions, TrustCSI™ information security solutions, DataHOUSE™ cloud data center solutions, and SmartCLOUD™ cloud computing solutions.With the motto “Innovation Never Stops,” we leverage innovative technologies to boost technology empowerment (+AI). Embracing AI, AR, Big Data, IoT, and other cutting-edge emerging technologies we aim to unlock technical potential. By integrating deep learning and intelligent data analysis technologies, we transform these technologies into data empowerment (AI+) generative applications, reshaping the Intelligence Operation Journey of enterprises.With our Global-Local capabilities, we are committed to providing our customers with one-stop-shop ICT solutions with superior quality. Having a worldwide footprint across nearly 160 countries and regions, including Asia, Europe and America, Africa, the Middle East, and Central Asia, our global network resources connect nearly 170 points of presence (POPs), 60+ SDWAN gateways, 21 Cloud service centers, 30+ data centers, and three dedicated 24x7 Security Operations Centers (SOCs). We are certified with a series of international certifications, including SD-WAN Ready, ISO 9001, 14001, 20000, 27001, and 27017, to ensure our services compliance with international standards and resources for enterprises. We offer local professional services, superior delivery capabilities as well as exceptional customer experience and best practices through our global presence and extensive industry know-how, becoming a leading integrated intelligent ICT service provider to enterprise customers.For more information, please visit www.citictel-cpc.comMedia Contacts:Catherine YuenCITIC Telecom CPC(852) 2170 7536Email: catherine.yuen@citictel-cpc.com Copyright 2024 ACN Newswire via SeaPRwire.com.
ISTANBUL, October 18, 2024 - (ACN Newswire via SeaPRwire.com) - The 15th Turkish-Arab Economic Forum (TAFF 2024), aimed at deepening relations between Turkiye and the Gulf countries and defining joint strategies for the region, took place yesterday in Istanbul.The Forum saw the attendance of many key figures from the Gulf countries, including Kuwait's Minister of Finance Noora Suleiman Salem Al-Fassam, Iraq's Minister of Finance Taif Sami Mohammed, Egypt's Deputy Minister of Finance Ahmed Kouchouk, Tunisia's Minister of Economy and Planning Samir Abdelhafidh, Libya's Minister of Finance Dr Kalid Al-Mabrouk, President of the Turkish Investment Fund Baghdad Amreyev, Secretary General of the Egyptian Federation of Arab Chambers Dr Khaled Hanafy, Regional Director of the Saudi International Finance Corporation Fawaz Bilbeisi, Director of the World Bank GCC Cooperation Safaa El Tayeb El-Kogali, Partner at the UK's DWF Solomon Ebere, Board Member of the Qatar Chamber Mohamed Bin Ahmed Al Obaidly, and Vice President of International Business Development of the United Arab Emirates Khalid Al Marzooqi.Turkiye's Minister of Treasury and Finance Mehmet Simsek evaluated global and regional strategies.In his speech at the 15th Turkish-Arab Economic Forum, Minister of Treasury and Finance Mehmet Simsek highlighted the decline in inflation and the slowdown in monetary policies. He emphasized that global trade will continue in November, pointing out that while there are challenges, there are also opportunities in this process. Mehmet Simsek further noted that he expects an increase in cooperation across various sectors, emphasizing that partnerships in energy, manufacturing, technology, and machinery are crucial for realizing the region's potential and he expressed his support for diversification strategies.Dr. Erkan Kork stated that Turkiye and the Gulf countries could build a shared future.Speaking at the 15th Turkish-Arab Economic Forum, Dr. Erkan Kork, Chairman of the Board of BankPozitif, highlighted that the participating countries share the same geography, history, and values, and emphasized that joint steps would be stronger and more effective. He noted that building a shared future with the available know-how, technology, and investments is vital for unlocking the region's potential.BankPozitif Chairman Dr Erkan Kork at the 15th Turkish Arab Economic ForumExpressing pride in Turkiye's positioning as a fintech hub, Dr Erkan Kork predicted that Turkiye would play a leading role on the global stage in various fields in the near future. He also stressed the importance of forums, fairs and events like this for fostering relationships between the business world and governments of different countries.In his speech, Dr Erkan Kork pointed out that Turkiye is in a very strong position in terms of innovation and information technology, noting that while processing times in many sectors in Europe are long, they are much shorter in Turkiye. Dr. Erkan Kork also highlighted Turkiye's high level of competitiveness in recent years.At the forum, which had a high participation rate, Fatih Karahan, Governor of the Central Bank of the Republic of Turkiye, Burak Dagloglu, Member of the Board of Directors of the Turkiye Wealth Fund, and Rfat Hisarckloglu, President of the Union of Chambers and Commodity Exchanges of Turkiye, were also among the speakers.Source: BankPozitif, https://www.bankpozitif.com.trSait Inanc, +90533 722 49 69, info@bankpozitif.com.tr* This press release is issued through EuropeNewswire.Net (www.europenewswire.net) and distributed by EmailWire (www.emailwire.com) – the gloabal newswire that provide Press Release Distribution with Guaranteed Results™. Copyright 2024 ACN Newswire via SeaPRwire.com.
HONG KONG, Oct 18, 2024 - (ACN Newswire via SeaPRwire.com) - Everest Medicines (1952.HK) closed today with a 20.46% increase, hitting a high of HKD 28.6. The company's stock price has been steadily rising since the release of its interim results, with today's trading volume reaching HKD 291 million. Market updates show that BOCOM International released a report assigning an 'outperform' rating to the Chinese pharmaceutical sector, with Everest Medicines being one of the key recommended stocks.Recently, the Hong Kong government released a policy address with numerous measures aimed at attracting overseas capital to Hong Kong, which has been a positive driver for the Hong Kong stock market. Additionally, negative sentiment in the innovative drug sector is gradually fading, and the market is now focusing on companies with profit potential and valuation recovery resilience.According to Everest Medicines' 2024 interim financial report, the company saw a significant revenue increase in the first half of the year, reaching RMB 302 million, representing a 158% growth compared to the second half of last year, marking the first time the company has achieved commercial profitability. The company's core products, Nefecon® and XERAVA® (the world's first-in-class fluorocycline antibiotic), have already been commercialized, with three products expected to be launched by the end of the year. In terms of innovative research and development, Everest Medicines owns an mRNA platform with full intellectual property rights and global benefits, dedicated to developing both preventive and therapeutic mRNA products. The company expects to achieve full-year sales of RMB 700 million by 2024 and aims to break even by the end of 2025.As BOCOM International released a report, it highlighted that innovative drug companies with abundant short-term catalysts, strong profit growth potential, or clear break-even timelines, along with significant valuation recovery potential, are worth close attention. Investors are also advised to focus on small and mid-sized innovative pharmaceutical companies whose market value diverges significantly from their fundamentals. These companies are expected to experience a strong rebound as liquidity improves.Over the past two months, Everest Medicines' stock has risen by over 65%. Recently, the unexpected adjustments in domestic monetary policy further energized capital markets. The continuous rise in both Hong Kong and mainland Chinese stock markets highlights the innovative drug sector as a key area of focus, given its long-term valuation bottoming and significant growth potential, making it a highly attractive investment in this market rally. Copyright 2024 ACN Newswire via SeaPRwire.com.
SHENZHEN, CHINA, Oct 18, 2024 - (ACN Newswire via SeaPRwire.com) - China Medical System Holdings Limited (the “Group” or “CMS”) is pleased to announce that on 18 October, the first batch of prescriptions of ruxolitinib phosphate cream (the “ruxolitinib cream” or the “Product”) for qualified vitiligo patients were issued in the Greater Bay Area, at Zhongshan Chen Xinghai Hospital of Integrated Traditional Chinese and Western Medicine, Foshan Fosun Chancheng Hospital, and Dongguan Songshan Lake Tungwah Hospital. The Product’s new drug application (NDA) was approved by the Pharmaceutical Administration Bureau (ISAF) of Macau on 11 April 2024, and subsequently the Product was approved by the Guangdong Provincial Medical Products Administration on August 19 through the "Hong Kong and Macau Medicine and Equipment Connect" policy, which officially introduced ruxolitinib cream for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age, providing a novel treatment option for patients with relevant indication into designated medical institutions in the Mainland of Greater Bay Area.In addition, on 24 September, the NDA for vitiligo indication of ruxolitinib cream has been accepted by the National Medical Products Administration of China (NMPA). In accordance with the relevant regulations of the drug real-world data application pilot program in the Hainan Boao Lecheng International Medical Tourism Pilot Zone (the “Pilot Zone”), CMS has conducted a real-world study on ruxolitinib cream in China. The results have shown positive efficacy, which is consistent with the key outcomes of global pivotal clinical studies. All secondary efficacy endpoints showed a trend of benefit consistent with the primary efficacy endpoint, and the treatment effect for vitiligo continued to improve with longer treatment duration. Meanwhile, through the safety monitoring data of the Pilot Zone, no new safety events have been identified. Adverse events mostly had severity levels of grade 1 or 2. No adverse event (AE) leading to discontinuation or withdrawal, and no serious adverse event (SAE) related to the study drug occurred.If the Product is successfully approved for marketing in Mainland China, it will be the first prescription drug approved by NMPA for repigmentation in vitiligo, bringing this novel treatment hopes for Chinese vitiligo patients.Furthermore, on 12 August 2023, the Product was approved by Hainan Medical Products Administration for Urgent Clinical Import, and officially became available to applicable patients in the Pilot Zone on August 18, for the topical treatment of non-segmental vitiligo in adults and adolescents aged 12 and above with facial involvement. Benefiting from the Early and Pilot Implementation Policy granted by the state to Hainan Free Trade Port and the Pilot Zone, patients with vitiligo in China can apply for the Product in Boao Super Hospital first and receive treatment from the expert team. As of 30 June 2024, more than 3,200 patients have been treated with ruxolitinib cream in Boao Super Hospital.CMS has always been patient-oriented and innovation-driven based on clinical needs, continuously striving to improve drug accessibility. Benefited from the "Hong Kong and Macau Medicine and Equipment Connect" policy, ruxolitinib cream was approved for use in the Greater Bay Area and completed its first batch of prescriptions, shortening the time difference for Chinese vitiligo patients to use innovative drug and benefiting more domestic patients. Looking forward to the future, the Group will continuously strive to meet the unmet needs of Chinese patients, continuously explore novel drugs with international quality, and efficiently promote products’ clinical development and commercialization, so as to bring more quality pharmaceutical products through differentiated innovation-breakthrough, to safeguard the health and life-quality of patients.About ruxolitinib creamRuxolitinib cream (Opzelura), a novel cream formulation of Incyte’s selective JAK1/JAK2 inhibitor ruxolitinib, is approved by the U.S. Food & Drug Administration for the topical treatment of nonsegmental vitiligo in patients 12 years of age and older. As of now, it is the first and only treatment for repigmentation approved for use in the United States[1]. Ruxolitinib cream (Opzelura) is also approved in the U.S. for the topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis (AD) in non-immunocompromised patients 12 years of age and older whose disease is not adequately controlled with topical prescription therapies, or when those therapies are not advisable[2]. In Europe, ruxolitinib cream (Opzelura) is approved for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age[3].On 2 December 2022, the Group through a subsidiary of the Company, a dermatology medical aesthetic company (“CMS Skinhealth”) entered into a Collaboration and License Agreement (the “License Agreement”) with Incyte for topical formulations of ruxolitinib for the treatment of autoimmune and inflammatory dermatology diseases. In accordance with the License Agreement, the Group through CMS Skinhealth received an exclusive license to develop, register and commercialize the Product in Mainland China, Hong Kong Special Administrative Region, Macau Special Administrative Region, Taiwan Region and eleven Southeast Asian countries (Indonesia, Philippines, Vietnam, Thailand, Myanmar, Malaysia, Cambodia, Laos, Singapore, Timor-Leste and Brunei Darussalam) (the “Territory”) and a non-exclusive license to manufacture the Product in the Territory. The License Agreement commenced on its effective date and has a royalty term of ten years from the date of the commercial sale of the Product in the Territory (the “Royalty Term”). Upon the expiration of the Royalty Term, the License Agreement may be renewed for a period of ten years thereafter (the “Initial Extended Royalty Term”) as per certain conditions defined in the License Agreement. Upon the expiration of the Initial Extended Royalty Term, the License Agreement may be extended for a period otherwise agreed by both sides as per certain conditions defined in the License Agreement.Incyte has worldwide rights for the development and commercialization of the Product, marketed in the United States and Europe as Opzelura®. Opzelura and the Opzelura logo are registered trademarks of Incyte.About vitiligoVitiligo is a chronic autoimmune disease characterized by depigmentation of the skin, which results from the loss of pigment-producing cells known as melanocytes. It is estimated that there are approximately 14 million vitiligo patients in China[4]. Non-segmental vitiligo patients account for approximately 85% of them. Topical corticosteroids (TCS) and calcineurin inhibitors (CI) are used off-label for non-segmental vitiligo, however, these therapies have clinical deficiencies with long-term adverse reactions of long-term treatment or limited efficacy[5,6].About CMSCMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development of its advantageous specialty fields and expand business boundaries. While strengthening the competitiveness of the cardio-cerebrovascular/gastroenterology business, CMS independently operates its dermatology and medical aesthetics business, and ophthalmology business, aiming to gain leading positions in specialty therapeutic fields, whilst enhancing the scale and efficiency. At the same time, CMS has expanded its business territory to the Southeast Asian market, striving to become a "bridgehead" for global pharmaceutical companies to enter the Southeast Asian market, further escorting the sustainable and healthy development of the Group.Reference:1. Drug approval information can be found on the FDA official website, as follows: https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-topical-treatment-addressing-repigmentation-vitiligo-patients-aged-12-and-older2. Drug approval information can be found on the Incyte official website, as follows: https://investor.incyte.com/news-releases/news-release-details/incyte-announces-us-fda-approval-opzeluratm-ruxolitinib-cream3. Drug approval information can be found on the EMA official website, as follows: https://www.ema.europa.eu/en/medicines/human/EPAR/opzelura4. Ezzedine K, Eleftheriadou V, Whitton M, van Geel N. Vitiligo. Lancet. 2015;386(9988):74-84. doi:10.1016/S0140-6736(14)60763-75. Consensus on the diagnosis and treatment of vitiligo (2021 version)6. Kubelis-López DE, Zapata-Salazar NA, Said-Fernández SL, Sánchez-Domínguez CN, Salinas-Santander MA, Martínez-Rodríguez HG, Vázquez-Martínez OT, Wollina U, Lotti T, Ocampo-Candiani J. Updates and new medical treatments for vitiligo (Review). Exp Ther Med. 2021 Aug;22(2):797. doi: 10.3892/etm.2021.10229. Epub 2021 May 25. PMID: 34093753; PMCID: PMC8170669.CMS Disclaimer and Forward-Looking StatementsThis press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.Media ContactChina Medical System Holdings Ltd.CMS Investor RelationsWebsite: https://web.cms.net.cn/en/home/Source: China Medical System Holdings Ltd. Copyright 2024 ACN Newswire via SeaPRwire.com.
Washington, D.C., Oct 18, 2024 - (ACN Newswire via SeaPRwire.com) - Today marks the launch of the second edition of the Multilateralism Index from the International Peace Institute (IPI) and the Institute for Economics & Peace (IEP). The Index reveals that states remain engaged in the global multilateral system even as it increasingly struggles to address the crises it faces.Multilateralism Index 2024 ReportAn image of the front cover of the Multilateralism Index 2024 ReportKey resultsThe performance of the multilateral system declined across all five domains examined.Peace and security showed the steepest deterioration in performance, with the number of armed conflicts rising from 39 in 2013 to 55 in 2022.Climate action and human rights also saw significant declines in performance, despite increased engagement from member states.Participation in multilateral institutions has increased in most domains, even as performance has declined, indicating a shift from cooperation to contestation.Inclusivity improved across all domains, with steady growth in NGO engagement and women's representation in UN bodies.The Multilateralism Index 2024 presents a complex picture of global cooperation over the past decade, examining five crucial domains: Peace and Security, Human Rights, Climate Action, Public Health, and Trade. It reveals a contradiction: while participation in the multilateral system has largely held steady or even increased, its effectiveness in addressing global challenges has declined.Dr. Adam Lupel, IPI Vice President & COO said: "Over the past decade, we've witnessed a paradox in multilateralism. While participation in international institutions has largely held steady or even increased, the performance of the multilateral system in addressing global challenges has declined. This suggests a shift from cooperation to contestation at a time of transformation and rising global crises."The peace and security domain experienced the most significant deterioration in performance. Active armed conflicts increased from 39 in 2013 to 55 in 2022, with a notable rise in internationalized conflicts. The UN Security Council has seen more frequent use of the veto power, constraining its ability to respond to crises. However, states have not broadly pulled back from the UN peace and security architecture, and commitments in some areas, such as multilateral peacebuilding, have increased.Climate action presents another contradiction. Despite near-universal participation in the Paris Agreement and growing climate commitments, these commitments continue to fall short of necessary targets. Projections show an 8.8% increase in emissions by 2030, in stark contrast to the 43% decrease required to meet the critical 1.5°C target.The human rights domain exhibits a counterintuitive pattern. While engagement with UN human rights mechanisms has increased, global human rights protections have steadily declined. Most strikingly, members of the UN Human Rights Council consistently scored lower on human rights measures than the global average, indicating that many states are engaging less to advance human rights than to shape the direction of the system.Multilateral action on public health was significantly shaped by the COVID-19 pandemic, which reversed years of progress, particularly in areas such as childhood immunization. It also put the shortcomings of the global public health system in stark relief, spurring negotiations on an international pandemic agreement aimed at strengthening preparedness and response capabilities for future health crises.Trade is the one area where both performance and participation decreased. The paralysis of global trade negotiations and breakdown in adherence to global trade rules signal a shift away from multilateral approaches. This trend, combined with growing geopolitical tensions, creates challenges for global economic cooperation.Steve Killelea, Founder & Executive Chairman of IEP, commented: "The Multilateralism Index 2024 reveals a challenging trend: while engagement in global institutions has increased, their effectiveness has declined across key areas. There is a need to revitalize our multilateral system to address today's complex challenges."Despite these challenges, the Index highlights positive developments, particularly in the area of inclusivity. NGO engagement with the UN system has grown, and women's representation has increased across many UN bodies. However, the Global South remains underrepresented in many areas, suggesting that geographic inclusivity remains a work in progress.As the world contends with interconnected crises, from conflict to climate change, the Multilateralism Index 2024 provides valuable insights into the current state of global cooperation. It underscores the need for thoughtful reform to ensure that multilateral institutions can effectively address the complex challenges of the 21st century.Contact InformationMike KoslowskiIEP Senior Communications Advisormkoslowski@economicsandpeace.org+61418410531Related FilesMultilateralism Index 2024 - Full Press Release (1)Multilateralism Index 2024 - Full Press Release (1)SOURCE: International Peace Institute Copyright 2024 ACN Newswire via SeaPRwire.com.
HONG KONG, Oct 18, 2024 - (ACN Newswire via SeaPRwire.com) - As recent economic stimulus measures by the government of China boost consumer confidence, and propel a rally in domestic stock markets, consumption stocks have been leading the surge, closing strong in the third quarter of 2024 strong. DPC Dash – Domino’s Pizza China, ("DPC Dash" or the "Company") (1405.HK), Domino's Pizza's exclusive master franchisee in the China Mainland, the Hong Kong Special Administrative Region of China, and the Macau Special Administrative Region of China, has further optimized shareholder structure to deliver long-term and significant value to shareholders.In the third quarter of 2024, the Company announced its inclusion in the Hong Kong Hang Seng Composite Index and the Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect Programs, underscoring its market credibility and growth potential. The inclusion in both a major index and stock connect programs offered more liquidity. As of October 15, 2024, the company’s stock price has surged over 60% since its IPO on March 28, 2023, significantly outperforming the Hang Seng Composite Index during the same period[i]. In order to further optimize shareholder structure and enhance the Company’s trading liquidity, Domino’s Pizza LLC, an indirect wholly-owned subsidiary of Domino’s Pizza, recently announced an agreement to sell an aggregate of 10,000,000 of the Company’s shares, or 7.66% of its total issued share capital as of October 17, 2024, to purchasers including institutional investors through off-market block trades. Following this share sale, Domino’s Pizza LLC retains 6.21% of total issued share capital with a lock-up period of 90 days for its remaining shares. The enduring relationship between DPC Dash and DPZ remains robust. The allocation is an opportunity for DPC Dash to further improve liquidity and bring new dynamics to its shareholder structure. Notable international banks have rated DPC Dash as “Buy” or “Outperform”, showing confidence in the company’s fundamentals and stock performance.DPC Dash continues to demonstrate its market prowess with strategic growth, operational efficiency and customer satisfaction. The Company’s remarkable success can be largely attributed to its effective 4D strategy of Development, Delicious pizza at value, Delivery, and Digital. This comprehensive approach has enabled the company to serve high-quality, value-for-money pizzas to a steadily growing customer base. From 2021 to 2023, DPC Dash realized a Compounded Annual Growth Rate (CAGR) of 37.6% in revenue. In the first half of 2024, revenue reached RMB2.04 billion while both reported and adjusted net profit after tax turned positive for the first time.The Company’s “Go Deeper, Go Broader” strategy has been instrumental in its growth. As of September 30, 2024, DPC Dash operates 978 stores across 33 cities, reflecting a robust expansion with 210 new stores opened year-to-date. The combined total of net new stores added this year, stores currently under construction, and stores with signed agreements has reached approximately 100% of the full-year opening target for 2024. It is confident in maintaining this strong expansion dynamic, with plans to open its 1000th store in the fourth quarter of 2024 and open 300 to 350 new stores annually in 2025 and 2026. The store network expansion is supported by strong performance metrics, including holding 28 of the top 30 positions for first 30-day sales among Domino’s global network of over 21,000 stores as of the end of the third quarter of 2024. Since the current management took the helm in the third quarter of 2017, DPC Dash has since achieved 29 consecutive quarters of positive same-store sales growth (SSSG) despite market and industrial turbulence. Meanwhile, the company’s digital initiatives played a crucial role in driving customer engagement and loyalty. The company’s loyalty program boasted 21.7 million members as of September 2024, with 11 million new customers placing their first orders in the past 12 months with Domino’s Pizza China.Looking ahead, DPC Dash remains focused on its expansion plans and operational enhancements, aiming for sustainable, profitable growth in China’s vast pizza market through continual innovation and optimization. The company’s resilient business model and strategic initiatives position it well for continued success in this competitive industry. The company will continue to strengthen its market position and add value to consumers by constantly enhancing product quality, service level, and customer experience.[i] Based on closed stock price of DPC Dash and HSCI of March 28, 2023 and October 15, 2024. Copyright 2024 ACN Newswire via SeaPRwire.com.
San Francisco, CA & Hanoi, Oct 17, 2024 - (ACN Newswire via SeaPRwire.com) - VPBank, one of Vietnam’s largest private banks, partners with CleverTap, the all-in-one customer engagement platform, to deepen understanding of customers and their aspirations and use the insights to deliver hyper-personalized experiences to users, at scale. VPBank aims to elevate customer experience and drive higher conversions on products and offers through highly targeted campaigns built on complex, real-time segmentation that quickly connects with customers. Through this association with CleverTap, VPBank’s objective is to improve engagement, deepen relationships and drive higher retention, while keeping costs low.Established in 1993, VPBank operates in a wide variety of businesses including retail banking, corporate banking, wealth management, and consumer finance. VPBank aims to become a top-ranking financial institution among joint stock commercial banks in Vietnam, in terms of business scale, market share, and service quality. Leveraging CleverTap’s AI/ML-powered capability suite, Clever.AI, VPBank will be able to hyper-personalize its engagement via multiple automation and journeys. It will enable a seamless and omnichannel onboarding experience for new users, driving higher success rates for key milestones such as registration and the first transaction. With the unified customer view on CleverTap, VPBank can identify high-intent users and target them with contextual and relevant offerings, achieving an increase in customer lifetime value.Varun Krishna, Head of Digital Marketing, VPBank said, “We’ve always strived to maintain our position as one of Vietnam’s leading financial institutions. In an increasingly competitive banking landscape, delivering personalized and meaningful customer experiences is paramount. Partnering with CleverTap empowers us to harness advanced AI-driven insights, enabling us to engage our customers more effectively and tailor our offerings to their unique needs across digital channels. This collaboration not only enhances our ability to connect with customers on a deeper level but also drives sustained growth and loyalty. Together, we are committed to setting new standards in customer engagement and positioning VPBank as the most trusted and preferred bank in Vietnam.”Mai Vo, Country Manager, CleverTap said, “Vietnam’s banking sector is at the precipice of a new era of growth. Our partnership with VPBank couldn’t be timed better. With a legacy of innovation and customer-centricity, VPBank has consistently set benchmarks in the Vietnamese banking industry. Their commitment to using technology for crafting exceptional customer experiences aligns perfectly with our vision. Together, with CleverTap’s state-of-the-art omnichannel platform, personalizing and enhancing customer engagement has never been more seamless. This partnership is not only a testament to CleverTap’s expertise in driving conversion and retention but also underscores VPBank’s leadership in propelling Vietnam's banking sector into a new era of excellence”About CleverTapCleverTap is the leading all-in-one customer engagement platform that helps brands unlock limitless customer lifetime value. CleverTap is trusted by over 2000 brands like Domino’s, Levis, Jio, Papa John’s, Zomato, Kotak Bank, Air Asia, Carousell, TD Bank, and Tesco to help build personalized experiences for all their customers. The platform is powered by TesseractDB™ – the world’s first purpose-built database for customer engagement, offering speed and cost efficiency at scale.Backed by top-tier investors such as Accel, Peak XV Partners, Tiger Global, CDPQ and 360 One, the company is headquartered in San Francisco, with presence across Seattle, London, São Paulo, Bogota, Mexico, Amsterdam, Sofia, Dubai, Mumbai, Bangalore, Singapore, Vietnam, and Jakarta.For more information, visit clevertap.com or follow us on:LinkedIn: https://www.linkedin.com/company/clevertap/ X: https://twitter.com/CleverTap Forward-Looking StatementsSome of the statements in this press release may represent CleverTap's belief in connection with future events and may be forward-looking statements, or statements of future expectations based on currently available information. CleverTap cautions that such statements are naturally subject to risks and uncertainties that could result in the actual outcome being absolutely different from the results anticipated by the statements mentioned in the press release.Factors such as the development of general economic conditions affecting our business, future market conditions, our ability to maintain cost advantages, uncertainty with respect to earnings, corporate actions, client concentration, reduced demand, liability or damages in our service contracts, unusual catastrophic loss events, war, political instability, changes in government policies or laws, legal restrictions impacting our business, impact of pandemic, epidemic, any natural calamity and other factors that are naturally beyond our control, changes in the capital markets and other circumstances may cause the actual events or results to be materially different, from those anticipated by such statements. CleverTap does not make any representation or warranty, express or implied, as to the accuracy, completeness, or updated or revised status of such statements. Therefore, in no case whatsoever will CleverTap and its affiliate companies be liable to anyone for any decision made or action taken in conjunction.For more information:SONY SHETTYDirector, Communications, CleverTap+91 9820900036sony@clevertap.com ASHMIT CHAUDHARYAssociate Consultant, Archetype+91 8850752121ashmit.chaudhary@archetype.co Copyright 2024 ACN Newswire via SeaPRwire.com.
ATH-063 significantly increased the number of circulating regulatory T cells (Tregs) across all doses and demonstrated enrichment in six well-described genes related to induced Treg anti-inflammatory activitiesNo serious adverse effects or dose limiting toxicities were observed at any dose level, and ATH-063 demonstrated favorable pharmacokinetics (PK) The data provides clinical verification for Athos’ Proprietary AI2 (Artificial Intelligence for Autoimmune drug development) computational software platform which generated ATH-063LOS ANGELES, CA, Oct 17, 2024 - (ACN Newswire via SeaPRwire.com) - Athos Therapeutics, Inc. ("Athos"), a clinical stage biotechnology company pioneering the development of precision small molecule therapeutics for patients with immune-mediated diseases, today announced topline results for the company's Phase 1 clinical trial of ATH-063, an investigational oral small molecule G9A inhibitor and the company's lead asset in development for the treatment of inflammatory bowel disease (IBD).The clinical trial was a randomized, double-blind, placebo-controlled study in healthy volunteers designed to evaluate safety and PK as well as provide pharmacodynamic (PD) data to provide confirmation of ATH-063's proposed mechanism of action. The trial was conducted as sequential single ascending dose (SAD) (n=32) and multiple ascending dose (MAD) (n=32) arms, and a separate food-effect (FE) (n=12) arm. Four doses (25, 75, 150, and 250 mg) of ATH-063 were administered orally.PD data showed ATH-063 selective expansion and activation of Tregs, consistent with predictions made by Athos' AI2 platform:Statistically significant increases (p<0.001) in the number of blood Tregs were observed at all ATH-063 dose levels compared to placebo subjects, and demonstrated correlation between ATH-063 blood levels and number of TregsBlood ATH-063 concentration positively correlated with increase in multiple key biomarkers of Treg activity, including strong correlation with FOXP3 (p=0.003)Induced Tregs demonstrated enrichment of six well-described genes related to Treg anti-inflammatory activitiesSTAT5A, a key signaling molecule related to induced Tregs, was activated in all cohorts and doses (p=0.0003)PD data demonstrated correlation with key biomarkers of IBD disease activity, supporting further development of ATH-063 as a treatment for IBD:Blood ATH-063 concentration correlated (p=0.012)with reduction of OSM, a well-established biomarker related to TNFA resistanceBlood ATH-063 concentration correlated with reduction of calprotectin monomers, which is an established biomarker for IBDATH-063 was well tolerated across all dose groups: No serious adverse effect or dose limiting toxicities were observed at any dose levelRobust PK results and dose proportional increases in blood levels: ATH-063 showed favorable PK results with dose-proportional increases in blood ATH-063 concentrations throughout the study"The results of our first-in-human clinical trial of ATH-063 exceeded our high expectations," said Dimitrios Iliopoulos, PhD, MBA, Founder, President & CEO, Athos. "We used the Athos AI2 drug development platform to identify a previously unrecognized and novel therapeutic target, to create ATH-063, and to preclinically predict the compound's proposed mechanisms of action. We are delighted that these Phase 1 results serve as clinical verification for the predictions made by the Athos AI2 computational engine" added Dr. Iliopoulos."Our Phase 1 data showed that once daily, oral dosing of ATH-063 was well tolerated and showed expansion of Tregs," commented Allan Pantuck, MD, MS, FACS, Chairman, Founder & CMO. "We are excited to move to our next stage of clinical development in subjects with moderately to severely active ulcerative colitis. The rapid pace of the ATH-063 program, from initial target identification to a completed Phase 1 trial, was enabled by the use of our innovative approach to leveraging Artificial Intelligence for drug development."About ATH-063ATH-063 is a novel, investigational, AI-generated, oral, small molecule, G9A inhibitor in development for the treatment of inflammatory bowel disease and other autoimmune diseases. G9A is a central hub on a gene network that was identified by the Athos AI2 platform through the integration of multi-omic and longitudinal clinical data from Athos' IBD biorepository. ATH-063 is designed to directly target G9A enzymatic activity in human CD4 T cells and GI epithelial cells, acting both by suppressing pro-inflammatory responses through expansion and activation of regulatory T cells and inducing direct mucosal healing through regulation of tight junction proteins.About Athos TherapeuticsAthos Therapeutics is a clinical stage biotechnology company seeking to develop potential first-in-class therapeutics that significantly impact the lives of patients with autoimmune disorders and chronic inflammatory diseases. The Athos drug development platform begins with over 25,000 high-quality patient samples sourced from premier global hospital systems. Athos' AI2 platform identifies novel drug targets by integrating multi-omic and longitudinal clinical datasets and matches them to its small molecule computational chemistry platform. The AI2 platform includes the Athos data lake, singular well-established omics workflows, and an integrative deep machine learning engine. The company's lead drug compound is ATH-063, an investigational, oral small molecule G9A inhibitor for inflammatory bowel disease.Athos is also developing a pipeline of additional small molecule approaches for various autoimmune diseases.Additional information about Athos Therapeutics can be found at https://athostx.com/Contact:Athos Therapeutics, Inc.Keith Hoffman, PhD, Chief Business Officerkhoffman@athostx.comSOURCE: Athos Therapeutics, Inc. Copyright 2024 ACN Newswire via SeaPRwire.com.
- The two major electronics fairs concluded today, attracting over 60,000 industry buyers from 136 countries and regions- 53% of respondents in an on-site survey expect overall sales to increase over the next 12-24 months, while 43% expect sales to remain stable- Most respondents believe there is a “very promising” or “promising” market potential for wearable electronic products (65%) and robotics technology (59%)HONG KONG, Oct 16, 2024 - (ACN Newswire via SeaPRwire.com) - The Hong Kong Electronics Fair (Autumn Edition), organised by the Hong Kong Trade Development Council (HKTDC), and electronicAsia, jointly organised by the HKTDC and MMI Asia Pte Ltd, concluded their physical exhibitions today.The four-day events attracted more than 60,000 industry buyers from 136 countries and regions. The number of buyers from Malaysia, Türkiye, Argentina and the UAE increased from last year. This reflects the exhibitions' status as important sourcing platforms for the industry.Sophia Chong, Deputy Executive Director of the HKTDC, said: "The global trend towards smart living is driving demand for innovative products and solutions. The Electronics Fair and electronicAsia serve as efficient platforms for the industry, enabling exhibitors to showcase their electronic products and technology solutions to buyers. We are pleased to see exhibitors and buyers successfully exploring business opportunities at the exhibitions, which are expediting Hong Kong's development into an international innovation and technology (I&T) centre.”In late October, the HKTDC will host the Hong Kong International Lighting Fair (Autumn Edition), Hong Kong International Outdoor and Tech Light Expo and ECO Expo Asia to create more cross-industry business opportunities.Industry optimistic about India, the Middle East, Latin AmericaAn independent survey agency commissioned by the HKTDC interviewed 1,091 Electronics Fair buyers and exhibitors about growth prospects for the industry. 53% of respondents expect overall sales to increase in the next 12-24 months, while 43% anticipate that they will remain stable. Most respondents believe that the electronics industry has the most growth potential in emerging markets, such as India, the Middle East and Latin America over the next two years, followed by Korea, Mainland China, Australia and the Pacific Islands.In terms of trends in electronic products, most respondents believe there is a “very promising” or “promising” market potential for wearable electronic products (65%) and robotics technology (59%).Meanwhile, 56% of respondents believe that the market potential for e-sports products and equipment is high. Most respondents consider these products to have the greatest growth potential in North America and Northern and Western Europe.Exhibitors attract quality buyers at fairsThis year's Electronics Fair featured more than 20 zones, gathering the latest electronic products and innovative solutions from global exhibitors in areas such as smart cities, smart mobility, gerontechnology and digital entertainment.First-time exhibitor and Founder of Zunosaki Limited, Newmen Ho, promoted the company's hand rehabilitation robot in the Startup Zone, seeking Mainland China and overseas distributors, partners and investors. In the first half of the exhibition, he met potential buyers from Taiwan’s nursing homes and from Korea. Additionally, a buyer from India expressed interest in applying the company's robotic hand technology across different industries.Hong Kong's renowned consumer electronics brand Momax achieved impressive results at the fair. The company's Founder and CEO John Cheng stated that in the first two days of the Fair, the team met some 60 buyers from the Asia-Pacific region and Europe. Momax also formed a long-term partnership with a publicly listed company in Papua New Guinea and is currently discussing an initial order valued at US$50,000.Additionally, through HKTDC’s Click2Match smart business matching platform, the company connected with another quality buyer from Australia, with the intent to collaborate long-term. Mr Cheng said: "Hong Kong's exhibitions are world-class, featuring high-quality buyers from a diverse range of countries. This year's Autumn Electronics Fair saw a significant turnout, and the buyers were very engaged. We will definitely participate again next year."Dongguan Maochang Printed Circuit Board Ltd, which develops technological solutions, participated in electronicAsia to stay updated on industry trends and identify potential buyers. The company's Sales Director, Michael Tsang, said: "Expanding onto the international stage is our primary goal for participating in the exhibition. I am glad that we met with over 200 potential buyers in the first three days to gain a deeper understanding of customer needs."Buyer seeks new products to expand marketVinal Patel, Chief Commercial Officer of UK buyer Brand Collective, has been attending the Electronics Fair for over 20 years. During the first two days of this year's fair, he secured over US$2 million worth of purchases, including charging cables, power banks and wireless speakers from two exhibitors. He is also considering expanding the range of products he distributes after discovering new offerings at the Fair. Mr Patel said: "The line-up at the exhibition gets better every year, even more impressive than before the pandemic. I will definitely participate in the Electronics Fairs in April and October in the future."Turkish buyer and Co-founder of Robotistan Elektronik Tic AS, Yusuf Gündogdu, visited electronicAsia with a purchasing budget of around U$100,000-200,000 for electronic products. He said: "The Electronics Fair is the best opportunity for me to interact face-to-face with exhibitors from around the world. I always find the best prices here. Meeting the founders of start-ups in the Startup Zone excites me. These companies are poised to become some of the best in the future and will drive market development through innovation, which I eagerly look forward to."The organisers held 78 events and forums during the exhibitions, inviting industry leaders to share unique insights and the latest industry information. These events included the Symposium on Innovation & Technology, Hong Kong Electronic Forum and Reliability Assurance for Electronic Systems Forum. Other on-site activities catered to start-ups, including investment matching, the Hong Kong Value Creation for Technology: Pitching Competition, Meet the Mentors sessions and Start-up Smart Launch.Under the EXHIBITION+ hybrid model, exhibitors and buyers can use the Click2Match smart business matching platform to conduct online meetings, in addition to attending the physical fair. Exhibitors and buyers can still explore business opportunities and conduct online negotiations through Click2Match until 23 October.Photo Download:https://bit.ly/3BVmX2RHong Kong Electronics Fair (Autumn Edition) and electronicAsia successfully concluded. The four-day events attracted over 60,000 buyers from 136 countries and regionsThis year's Symposium on Innovation & Technology, themed 'When Two Worlds Collide: The Confluence of Digital Twins & Real-Life Applications', featured heavyweight guests and attracted numerous industry professionalsThe Hall of Fame gathered consumer electronic products from renowned brands worldwide. Among them, Asia Kingston (HK) Limited, specialising in brand licensing, presented a gaming chair featuring the NASA logoLocal brands, including well-known electronic brand Momax, promoted their products to global buyersThe Tech Hall showcased products using a variety of cutting-edge technologies, including 3D printing, Internet of Things, robotics, AR and XRThis year's Electronics Fair introduced a Digital Entertainment Experience Zone, where buyers could try and explore products on-siteThe concurrent electronicAsia featured multiple zones, exhibiting products, such as electronic components and parts, keyboards and switches, power supply equipment and moreThe Hong Kong Electronic Forum, co-organised by the HKTDC, MMI Asia Pte Ltd and the Hong Kong Electronic Industries Association, was themed “Innovation Unleashed: The Intersection of Microelectronics, AI, and Open-Source Ecosystems”WebsitesHong Kong Electronics Fair (Autumn Edition): hkelectronicsfairae/enelectronicAsia: electronicasia/enMedia enquiriesPlease contact the HKTDC’s Communications & Public Affairs Department:Katy WongTel: (852) 2584 4524Email: katy.ky.wong@hktdc.orgSnowy ChanTel: (852) 2584 4525Email: snowy.sn.chan@hktdc.orgHKTDC Media Room: https://mediaroom.hktdc.com/enAbout the HKTDCThe Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong ’s trade. With 50 offices globally, including 13 in Mainland China, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly SMEs, in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via trade publications, research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus. Copyright 2024 ACN Newswire via SeaPRwire.com.
HONG KONG, Oct 17, 2024 - (ACN Newswire via SeaPRwire.com) - Guotai Junan International Holdings Limited (“Guotai Junan International”, “GTJAI”, the “Company” or the “Group”, stock code: 1788.HK) is pleased to announce that the Company has participated in the Good Employer Charter Scheme launched by the Hong Kong Labour Department for the sixth consecutive year, committed to adopting good personnel management practices and creating a family-friendly working environment for employees.The Good Employer Charter 2024 features the theme of “Supportive Family-friendly Good Employer”. Employers of different industries and scales are encouraged to adopt and enhance employee-oriented family-friendly employment practices, putting themselves in the employees’ shoes in discharging both work and family obligations, so as to create a family-friendly working environment. This signing of the Good Employer Charter demonstrates the Company’s efforts in employee care and creating a harmonious and inclusive working environment.GTJAI has always cared for its employees. Adhering to the business philosophy of “Talent as the First Resource” and pursuing the talent concept of “People-oriented, Collaborative Cooperation”, GTJAI considers employees as its core asset and has always been devoted to creating an inclusive and healthy working environment, and providing adequate resources to support employees’ growth and development. In the future, GTJAI will continue to strive to improve employee satisfaction, create a more friendly working environment, and contribute to building a harmonious and inclusive society. Copyright 2024 ACN Newswire via SeaPRwire.com.
